Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11662
Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn ' s Disease in Children: PRESENCE Study from SEGHNP
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorMoriczi, Melinda; Pujol-Muncunill, Gemma; Martin-Masot, Rafael; Jimenez Trevino, Santiago; Segarra Canton, Oscar; Ochoa Sangrador, Carlos; Pena Quintana, Luis; Gonzalez Santana, Daniel; Rodriguez Martinez, Alejandro; Rosell Camps, Antonio; Armas, Honorio; Barrio, Josefa; Gonzalez de Caldas, Rafael; Rodriguez Salas, Monica; Balmaseda Serrano, Elena; Donat Aliaga, Ester; Bodas Pinedo, Andres; Vaquero Sosa, Esther; Vecino Lopez, Raquel; Solar Boga, Alfonso; Moreno Alvarez, Ana; Sanchez Sanchez, Cesar; Tolin Hernani, Mar; Gutierrez Junquera, Carolina; Martinon Torres, Nazareth; Leis Trabazo, Maria Rosaura; Javier Eizaguirre, Francisco; Garcia Peris, Monica; Medina Benitez, Enrique; Fernandez Caamano, Beatriz; Vegas Alvarez, Ana Maria; Crespo Valderrabano, Laura; Alonso Vicente, Carmen; Rubio Santiago, Javier; Galera-Martinez, Rafael; Garcia-Romero, Ruth; Ros Arnal, Ignacio; Fernandez Cebrian, Santiago; Lorenzo Garrido, Helena; Viada Bris, Javier Francisco; Velasco Rodriguez-Belvis, Marta; Bartolome Porro, Juan Manuel; Blanco Rodriguez, Miriam; Barros Garcia, Patricia; Botija, Gonzalo; Chicano Marin, Francisco Jose; La Orden Izquierdo, Enrique; Crehua-Gaudiza, Elena; Navas-Lopez, Victor Manuel; Martin-de-Carpi, Javier
Document typeresearch article
CitationMoriczi M, Pujol-Muncunill G, Martin-Masot R, Jimenez Trevino S, Segarra Canton O, Ochoa Sangrador C, et al. Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn ' s Disease in Children: PRESENCE Study from SEGHNP. Nutrients. 2020 Apr;12(4):1012.
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn ' s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014-2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 +/- 2.5 years. The median EEN duration was 8 weeks (IQR 6.6-8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn's Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (<mu>g/g) decreased significantly after EEN (830 [IQR 500-1800] to 256 [IQR 120-585] p < 0.0001). Patients with wPCDAI <less than or equal to> 57.5, FC < 500 <mu>g/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6-8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn's disease regardless of the location of disease and disease activity.
Keywordsinflammatory bowel disease
exclusive enteral nutrition
DeCSInducción de Remisión
Enfermedad de Crohn